Novavax's Shareholders Can Breathe a Sigh of Relief

Could Novavax (NASDAQ: NVAX) climb back into positive territory in the stock market this year? On the one hand, some investors are skeptical regarding the future of the COVID-19 vaccine market, and many biotechs specializing in this niche have taken it on the chin.

On the other hand, Novavax finally cleared one of its most important (and long overdue) regulatory milestones. What's next for the vaccine maker? Let's discuss Novavax's recent regulatory win and what it means for the company's future.

Continue reading

Source Fool.com